ClinicalTrials.gg
CompletedNCT05531682Updated Jun 21, 2024

A Study to Evaluate the Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis

A Phase 2 interventional study of Placebo and HB0017 in Plaque Psoriasis, sponsored by Huabo Biopharm Co., Ltd.. Completed at 21 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-06-21.

Sponsored by Huabo Biopharm Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 206 studies in Psoriasis with a site in China — 56 open to participants now, 66 under way, 22 of them phase 3. Psoriasis · China.

Enrollment
93rd of 182
160 · median 171
Started
2022
with 14 others
Phase 2
42 of 206
11 open now
Registered
91st of 206
by date
Lead sponsor
5 of 206
Huabo Biopharm Co., Ltd.

Among the 206 studies in Psoriasis with a site in China, this one is the 93rd largest by enrollment of the 182 interventional ones that give a count, is one of 15 that started in 2022, is one of 42 in phase 2, and was the 91st registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

56 of the 206 studies in Psoriasis with a site in China are open now. Recruiting first, the newest first:

51 more — sign in →

All 56 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Psoriasis with a site in China, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled, multi-center Phase 2 study to evaluate the efficacy and safety of HB0017 in subjects with moderate to severe plaque psoriasis.

Read the detailed description

This is a randomized, double-blind, placebo-controlled, multi-center Phase 2 study to evaluate the efficacy and safety of HB0017 in subjects with moderate to severe plaque psoriasis. The study will consist of 3 periods: up to 5 weeks screening period, 28 weeks treatment period, 8 weeks Safety Follow-Up period.

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

Keywords

  • HB0017
  • Chronic Plaque Psoriasis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Subject has provided
  • Diagnosis of chronic plaque psoriasis with or without psoriatic arthritis for at least 6 months prior to Screening
  • Psoriasis Area and Severity Index(PASI)>=12 and body surface area(BSA) >=10% and static Physician's Global Assessment (sPGA) score 3 or greater on a 5-point scale
  • Candidates for systemic psoriasis therapy and/or phototherapy and/or chemo phototherapy
  • Women who are at childbearing age(not pregnant or breast-feeding), and subjects and their partners voluntarily use methods deemed effective by the investigator during treatment and for at least 6 months after the last study medication

Key Exclusion Criteria:

  • Forms of psoriasis other than chronic plaque psoriasis.
  • History or evidence of active tuberculosis, Patients with evidence of latent tuberculosis may enter the trial after sufficient treatment according to protocol.
  • Positive results of confirmatory serology test for , , or syphilis at screening.
  • History of a serious or systemic infection within 4 weeks before screening.
  • History of of any organ system within the past 5 years.
  • Inadequate for prior drug therapy.
  • Previous use of secukinumab, ixekizumab or any other drug that targets Interleukin 17( IL-17) or IL-17 receptor.
  • Any medical conditions, in the opinion of the Investigator or the Sponsor's medical monitor, would place the subject at risk, interfere with study participation or study results interpretation.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
160 participants (actual)

Study arms

  • Experimental
    Experimental: HB0017 dosing regimen 1

    HB0017 low dose short intervals of subcutaneous injection

    Drug: HB0017

  • Experimental
    Experimental: HB0017 dosing regimen 2

    HB0017 low dose long intervals of subcutaneous injection

    Drug: HB0017

  • Experimental
    Experimental: HB0017 dosing regimen 3

    HB0017 high dose long intervals of subcutaneous injection

    Drug: HB0017

  • Placebo comparator
    Placebo Comparator: placebo group

    Placebo was subcutaneously injected into the 12 weeks turnover HB0017 subcutaneous injection

    Other: Placebo

Interventions

  • OtherPlacebo

    Subjects will receive several injections of Placebo

  • DrugHB0017

    Subjects will receive HB0017 in different dosing regimens

    Also known as: HB0017 dosing regimens

06

What researchers measure

Primary outcomes

  1. PASI 90 response

    Proportion of subjects who achieve Psoriasis Area and Severity Index (PASI) 90 response or higher at week 12

    Time frame: Week 12

  2. sPGA 0/1 response

    Proportion of subjects who achieve static Physician Global Assessment (sPGA) 0 or 1

    Time frame: Week 12

Secondary outcomes

  1. PASI 75 response

    Proportion of subjects who achieve PASI 75 response or higher

    Time frame: Week 12

  2. Adverse events

    Treatment Related Adverse events (TEAEs)/serious adverse events (SAEs)

    Time frame: From baseline through 36 weeks

  3. Immunity

    Number and proportion of subjects who developed anti-drug antibodies (ADAs) Following Study Treatment

    Time frame: From baseline through 36 weeks

  4. PK characteristics

    Population pharmacokinetics (PK), Apparent Total Clearance (CL/F), Apparent Volume of Distribution (V/F) of HB0017

    Time frame: From Baseline through 36 weeks

  5. PASI responses up to 36 Weeks

    Proportion of subjects who achieve PASI 50, PASI 75, PASI 90 , PASI 100 response up to 36 weeks

    Time frame: From Baseline through 36 weeks

  6. sPGA 0/1 up to 36 Weeks

    Proportion of subjects who achieve

    Time frame: From Baseline through 36 weeks

  7. PD characterestics

    HB0017 concentrations in serum at different time points

    Time frame: From Baseline through 36 weeks

  8. PASI score change

    change in PASI From Baseline to Week 36

    Time frame: From Baseline through 36 weeks

  9. Percent change in PASI

    Percent change in PASI From Baseline to Week 36

    Time frame: From Baseline through 36 weeks

07

Study locations

21 sites
  • The First Affiliated Hospital of Bengbu Medical College
    Bengbu, Anhui, China
  • The First Affiliated Hospital of Anhui Medical University
    Hefei, Anhui, China
  • The Second Hospital of Anhui Medical University
    Hefei, Anhui, China
  • The First Affiliated Hospital of Wannan Medical College
    Wuhu, Anhui, China
  • Dermatology Hospital of Southern Medical University
    Guangzhou, Guangdong, China
  • Guangdong Provincial People's Hospital
    Guangzhou, Guangdong, China
  • The first hospital of Hebei Medical University
    Shijiazhuang, Hebei, China
  • The Second Xiangya Hospital of Central South University
    Changsha, Hunan, China
  • The Third Xiangya Hospital of Central South University
    Changsha, Hunan, China
  • Xiangya Hospital of Central South University
    Changsha, Hunan, China
  • Affiliated Hospital of Jiangsu University
    Zhenjiang, Jiangsu, China
  • Dermatology Hospital of Jiangxi Province
    Nanchang, Jiangxi, China
  • Shandong Provincial Hospital Affiliated to Shandong First Medical University
    Jinan, Shandong, China
  • Skin Disease Hospital of Shandong First Medical University
    Jinan, Shandong, China
  • Yantai Yuhuangding hospital
    Yantai, Shandong, China
  • Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
  • The First Affiliated Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
  • The Third People's Hospital of Hangzhou
    Hangzhou, Zhejiang, China
  • Peking University People's Hospital
    Beijing, China
  • Peking University Third Hospital
    Beijing, China
  • Shanghai Skin Disease Hospital
    Shanghai, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in May 2023, 6 months.

Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 6 months is below that.

Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2022
First posted
Sep 8, 2022
StartActual
Oct 25, 2022
Primary completionActual
May 23, 2023
CompletionActual
Jan 4, 2024
Last update
Jun 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05531682
Lead sponsor
Huabo Biopharm Co., Ltd.
Responsible party
Sponsor
First posted
Sep 8, 2022
Start date
Oct 25, 2022
Primary completion
May 23, 2023
Completion
Jan 4, 2024
Last update
Jun 21, 2024

Study contacts

Jianzhong zhang
principal investigator · Peking University People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HB0017

Start the discussion